ArticleOncotarget2017

Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases.

Waleed Shady et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.